Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is a publicly traded Healthcare sector company. As of May 21, 2026, AMLX trades at $13.58 with a market cap of $1.43B and a P/E ratio of -8.66. AMLX moved +6.83% today. Year to date, AMLX is +19.49%; over the trailing twelve months it is +146.56%. Its 52-week range spans $2.60 to $18.61. Analyst consensus is strong buy with an average price target of $24.57. Rallies surfaces AMLX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes AMLX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $13.58 |
| Market Cap | $1.43B |
| P/E Ratio | -8.66 |
| EPS | $-1.53 |
| Dividend Yield | 0.42% |
| 52-Week High | $18.61 |
| 52-Week Low | $2.60 |
| Volume | 333 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-144.74M |
| Gross Margin | 0.00% |
8 analysts cover AMLX: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.57.